Agranulocytosis Induced by Vancomycin. Case Report and Literature Review
Horacio di Fonzo1, Melina Villegas Gutsch1, Augusto Castroagudin1
1Department of Internal Medicine, Hospital de Clínicas "José de San Martin", University of Buenos Aires, Buenos Aires, Argentina.
Abstract:
BACKGROUND Vancomycin has been used for decades to treat infections by Gram-positive bacteria, particularly those caused by methicillin-resistant staphylococci. Agranulocytosis is an infrequent complication of this antibiotic, postulated in its genesis a mechanism immune-mediated by antineutrophil antibodies and antineutrophil cytoplasm antibodies (ANCA). Treatment includes discontinuing vancomycin, and granulocyte colony-stimulating factor administration. CASE REPORT We present the case of a patient who developed agranulocytosis secondary to vancomycin during the treatment of an infectious endocarditis, which was reversed when the antibiotic was stopped. Concomitantly to neutropenia, he had ANCA positivity, which subsequently became negative. CONCLUSIONS Agranulocytosis induced by vancomycin is infrequent and generally occurs after day 12 of treatment. In most cases, like in our case, it is caused by an immune-mediated mechanism. More studies are needed to determine the pathogenic mechanism and the ANCA role in this adverse effect.
Insights
Vancomycin can rarely cause agranulocytosis, a serious condition of low white blood cells, often due to immune reactions. Stopping the antibiotic typically resolves this adverse effect.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Vancomycin is a critical antibiotic for Gram-positive bacterial infections, including MRSA.
- Agranulocytosis is a rare but severe adverse effect associated with vancomycin therapy.
- Immune-mediated mechanisms involving antineutrophil antibodies and antineutrophil cytoplasm antibodies (ANCA) are implicated in vancomycin-induced agranulocytosis.
Observation:
- This case report details a patient who developed agranulocytosis during vancomycin treatment for infectious endocarditis.
- The patient exhibited ANCA positivity concurrently with neutropenia.
- Resolution of agranulocytosis was observed upon discontinuation of vancomycin.
Findings:
- Vancomycin-induced agranulocytosis is infrequent, typically manifesting after 12 days of treatment.
- The adverse effect is predominantly driven by immune-mediated processes.
- The patient's ANCA positivity resolved as neutropenia improved after vancomycin cessation.
Implications:
- Understanding the immune-mediated pathogenesis of vancomycin-induced agranulocytosis is crucial.
- Further research is needed to elucidate the precise role of ANCA in this complication.
- This case highlights the importance of monitoring for hematological adverse effects during vancomycin therapy.
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Types of Reports III: Telephone and Verbal Reports
Here's an overview of each type:
Telephone Orders


